AU2011349256B2 - Methods for treating neurological conditions and compositions and materials therefor - Google Patents

Methods for treating neurological conditions and compositions and materials therefor Download PDF

Info

Publication number
AU2011349256B2
AU2011349256B2 AU2011349256A AU2011349256A AU2011349256B2 AU 2011349256 B2 AU2011349256 B2 AU 2011349256B2 AU 2011349256 A AU2011349256 A AU 2011349256A AU 2011349256 A AU2011349256 A AU 2011349256A AU 2011349256 B2 AU2011349256 B2 AU 2011349256B2
Authority
AU
Australia
Prior art keywords
decorin
traumatic
neurological condition
injury
spinal cord
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011349256A
Other languages
English (en)
Other versions
AU2011349256A1 (en
Inventor
Stephen Davies
Kenneth Hal Minor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scidec Therapeutics Inc
Original Assignee
Scidec Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scidec Therapeutics Inc filed Critical Scidec Therapeutics Inc
Publication of AU2011349256A1 publication Critical patent/AU2011349256A1/en
Assigned to SCIDEC THERAPEUTICS, INC. reassignment SCIDEC THERAPEUTICS, INC. Request for Assignment Assignors: SCIDEC, LLC
Application granted granted Critical
Publication of AU2011349256B2 publication Critical patent/AU2011349256B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2011349256A 2010-12-20 2011-12-20 Methods for treating neurological conditions and compositions and materials therefor Active AU2011349256B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061424769P 2010-12-20 2010-12-20
US61/424,769 2010-12-20
PCT/US2011/066199 WO2012088133A1 (en) 2010-12-20 2011-12-20 Methods for treating neurological conditions and compositions and materials therefor

Publications (2)

Publication Number Publication Date
AU2011349256A1 AU2011349256A1 (en) 2013-08-08
AU2011349256B2 true AU2011349256B2 (en) 2017-01-05

Family

ID=46235329

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011349256A Active AU2011349256B2 (en) 2010-12-20 2011-12-20 Methods for treating neurological conditions and compositions and materials therefor

Country Status (6)

Country Link
US (3) US9061047B2 (enExample)
EP (1) EP2654899B1 (enExample)
JP (1) JP5883027B2 (enExample)
AU (1) AU2011349256B2 (enExample)
ES (1) ES2582605T3 (enExample)
WO (1) WO2012088133A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011349256B2 (en) 2010-12-20 2017-01-05 Scidec Therapeutics, Inc. Methods for treating neurological conditions and compositions and materials therefor
WO2015089443A2 (en) * 2013-12-12 2015-06-18 The Brigham And Women's Hospital, Inc. Treating neurodegenerative disease
CN104173938B (zh) * 2014-08-29 2017-03-01 李从达 一种治疗脊髓栓系综合征的中药制剂
GB202314158D0 (en) * 2023-09-15 2023-11-01 Senorei Ltd Inhibition of vascular leakage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612038B2 (en) 1999-11-18 2009-11-03 Brown University Biglycan and related therapeutics and methods of use
US20080140056A1 (en) 2006-12-06 2008-06-12 Medtronic, Inc. Method for delivering large molecules to the brain
JP2010047533A (ja) * 2008-08-22 2010-03-04 Mitsubishi Gas Chemical Co Inc 脊髄損傷改善剤
WO2010065917A1 (en) * 2008-12-05 2010-06-10 The Regents Of The University Of California Methods of treating neurological disorders
AU2011349256B2 (en) 2010-12-20 2017-01-05 Scidec Therapeutics, Inc. Methods for treating neurological conditions and compositions and materials therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVIES et al. "Decorin supresses neurocan, brevican, phosphacan and NG2 expression and promotes axon growth across adult rat spinal cord injuries", European Journal of Neuroscience, 2004, Vol. 19, Pages 1226-1242. *
MINOR et al. "Decorin, erythroblastic leukaemia viral oncogene homologue B4 and signal transducer and activator of transcription 3 regulation of semaphorin 3A in central nervous system scar tissue", Brain, 2011, Vol. 134, Pages 1140-1155. *

Also Published As

Publication number Publication date
WO2012088133A1 (en) 2012-06-28
US20150250859A1 (en) 2015-09-10
JP5883027B2 (ja) 2016-03-09
US20120157976A1 (en) 2012-06-21
US20170136098A1 (en) 2017-05-18
EP2654899B1 (en) 2016-05-25
EP2654899A4 (en) 2014-08-20
US9592276B2 (en) 2017-03-14
JP2014500327A (ja) 2014-01-09
ES2582605T3 (es) 2016-09-14
EP2654899A1 (en) 2013-10-30
HK1190652A1 (zh) 2014-07-11
US9061047B2 (en) 2015-06-23
US10258670B2 (en) 2019-04-16

Similar Documents

Publication Publication Date Title
Burnside et al. Manipulating the extracellular matrix and its role in brain and spinal cord plasticity and repair
Xie et al. Exendin-4 attenuates neuronal death via GLP-1R/PI3K/Akt pathway in early brain injury after subarachnoid hemorrhage in rats
De Albornoz et al. Non-surgical therapies for peripheral nerve injury
US10258670B2 (en) Methods for treating neurological conditions and compositions and materials therefor
Shields et al. Benefit of chondroitinase ABC on sensory axon regeneration in a laceration model of spinal cord injury in the rat
Umebayashi et al. Blockade of gap junction hemichannel protects secondary spinal cord injury from activated microglia-mediated glutamate exitoneurotoxicity
Alder et al. Genetic and pharmacological intervention of the p75NTR pathway alters morphological and behavioural recovery following traumatic brain injury in mice
AU2011349256A1 (en) Methods for treating neurological conditions and compositions and materials therefor
JP2006521405A (ja) 発作回復におけるエリトロポイエチンの使用
HK1190652B (en) Decorin for use in treating traumatic neurological conditions via intrathecal administration
US10160791B2 (en) Protamine in treatment of neuronal injuries
Shan et al. Galectin-3 inhibition reduces fibrotic scarring and promotes functional recovery after spinal cord injury in mice
CN1278184A (zh) 预防或治疗局部缺血性疾病的药剂
Hasenöhrl et al. Facilitation of learning following injection of the chondroitin sulfate proteoglycan biglycan into the vicinity of the nucleus basalis magnocellularis
US20210128701A1 (en) Compositions comprising adamts13 for use in methods for the recanalization of occluded blood vessels in an infarction
Gunay et al. The effectiveness of tetanus toxin on sciatic nerve regeneration: a preliminary experimental study in rats
US20060122116A1 (en) Treatment for disorders of the peripheral nervous system
Lopes‐Azevedo et al. Cardiovascular effects of the microinjection of L‐proline into the third ventricle or the paraventricular nucleus of the hypothalamus in unanesthetized rats
Shanmugalingam Exploring novel molecular approaches to promote repair of the damaged nervous system: A role for Neuronal Pentraxin 2
Lipponen The Effect of Intrathecally Administered HB-GAM (Pleiotrophin) in the Cervical Hemisection and Cervical Hemicontusion Mouse Models of Spinal Cord Injury
Milton Chronic Systemic Manipulation of Axonal Inhibitory Perineuronal Net and rPTPσ Promotes Forelimb Recovery and Neuroplasticity
WO2024081656A1 (en) Bone sialoprotein compositions and methods of using thereof
Balch Acute Mechanisms of Skeletal Muscle Decline and Rehabilitative Recovery Following Ischemic Stroke
Urban Targeted Restoration of Respiratory Neural Circuitry following Cervical Spinal Cord Injury
Veronesi Improving Axonal Regeneration: Side-to-Side Bridges Coupled with Local Delivery of Glial Cell Line-Derived Neurotrophic Factor (GDNF)

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SCIDEC THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): SCIDEC, LLC

FGA Letters patent sealed or granted (standard patent)